(Q50045992)

English

Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature.

scientific article published on 29 December 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

0 references

Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. (English)

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

0 references

liver cirrhosis

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mitsuhiko Moriyama

14

object named as

Mitsuhiko Moriyama

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

2

object named as

Tatsuo Kanda

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

author name string

Yuki Haga

1

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Shin Yasui

3

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Masato Nakamura

4

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Yoshihiko Ooka

5

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Koji Takahashi

6

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Shuang Wu

7

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Shingo Nakamoto

8

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Makoto Arai

9

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Tetsuhiro Chiba

10

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Hitoshi Maruyama

11

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Osamu Yokosuka

12

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Nobuo Takada

13

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Fumio Imazeki

15

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Naoya Kato

16

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

language of work or name

0 references

publication date

29 December 2017

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

9

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

4

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

5509-5513

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

Preliminary study of two antiviral agents for hepatitis C genotype 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

New antiviral therapies for chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

22 May 2018

APASL consensus statements and recommendation on treatment of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

14 August 2018

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

14 August 2018

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5797068

14 August 2018

Hepatitis C and hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29435197

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.18632/ONCOTARGET.23768

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

1 reference

Europe PubMed Central

24 February 2018

http://europepmc.org/abstract/PMC/5797068

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50045992&oldid=2120727607"